Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Acta Parasitol ; 69(1): 1090-1094, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38493433

RESUMO

BACKGROUND: Co-infection with other microorganisms such as parasites in patients with COVID-19 can affect the clinical outcome and require prompt diagnosis and appropriate therapy. CASE PRESENTATION: We present a case of an adult male with chest pain, dyspnea, cough, diplopia, and anorexia who was confirmed to have acute COVID-19 pneumonia. 2 weeks prior to admission, a hydatid lung cyst was identified on examination, but the patient refused surgery. Thoracoabdominal computed tomography (CT) revealed a rupture of the lung hydatid cyst and co-infection with COVID-19. The patient has prescribed a treatment protocol for COVID-19 and albendazole. Despite measures taken to manage severe inflammation and decreasing blood oxygen levels, the patient required admission to the intensive care unit (ICU) and intubation. After approximately 3 weeks of hospitalization, the patient was successfully extubated and discharged uneventfully from the hospital. Oral albendazole was prescribed for follow-up treatment. CONCLUSION: Our case highlights the importance of considering hydatid cysts in the differential diagnosis of patients with COVID-19, especially those living in endemic areas.


Assuntos
Albendazol , COVID-19 , Equinococose Pulmonar , COVID-19/complicações , COVID-19/diagnóstico , Humanos , Masculino , Equinococose Pulmonar/complicações , Equinococose Pulmonar/diagnóstico , Equinococose Pulmonar/diagnóstico por imagem , Albendazol/uso terapêutico , Albendazol/administração & dosagem , Tomografia Computadorizada por Raios X , SARS-CoV-2 , Coinfecção/parasitologia , Coinfecção/diagnóstico , Pessoa de Meia-Idade , Pulmão/parasitologia , Pulmão/diagnóstico por imagem , Pulmão/patologia , Índice de Gravidade de Doença
2.
J Infect Public Health ; 17(5): 800-809, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38537575

RESUMO

This systematic review and meta-analysis study aimed to evaluate global Trichuris infection prevalence, assessing progress towards the WHO's 2030 target. We searched international databases from 2010-2023, categorizing data by regions and socio-economic variables using a random-effects model. Analyzing 757 articles covering 7154,842 individuals from 78 countries, the study found a pooled global prevalence of (6.64-7.57%), with the highest rates in the Caribbean (21.72%; 8.90-38.18%) and South-East Asia (20.95; 15.71-26.71%) regions. Southern Africa (9.58; 2.11-21.46%), Latin America (9.58; 2.11-21.46%), and Middle Africa Middle Africa (8.94; 6.31-11.98%) also exhibited high prevalence. Eastern Europe had the lowest prevalence at 0.16% (0.09-0.24). Approximately 513 (480-547) million people worldwide were estimated to harbor Trichuris. Moreover ∼1.5% of people tested worldwide (2010-2023) had a moderate to heavy intensity of infection. The study emphasizes the persistent global health threat of Trichuris infection, urging tailored strategies for effective control and prevention on a global scale.


Assuntos
Saúde Global , Tricuríase , Trichuris , Humanos , Tricuríase/epidemiologia , Prevalência , Saúde Global/estatística & dados numéricos , Trichuris/isolamento & purificação , Animais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA